| Trial ID: | L5312 |
| Source ID: | NCT01586442
|
| Associated Drug: |
Eplerenone
|
| Title: |
Comparison of Eplerenone Versus Spironolactone in Heart Failure Patients With Glucose Intolerance or Type 2 Diabetes
|
| Acronym: |
SNOW
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Heart Failure|Type 2 Diabetes|Glucose Intolerance
|
| Interventions: |
DRUG: Eplerenone|DRUG: Spironolactone
|
| Outcome Measures: |
Primary: Glycated hemoglobin, Change in glycated hemoglobin, 4 months|Fasting glucose and lipid profile, 4 months|Plasma insulin, 4 months|Cortisol, 4 months|Adiponectin, 4 months|NT-proBNP, 4 months|PIIINP, 4 months |
|
| Sponsor/Collaborators: |
Sponsor: Montreal Heart Institute | Collaborators: Pfizer
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
62
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2012-03
|
| Completion Date: |
2018-07-29
|
| Results First Posted: |
|
| Last Update Posted: |
2022-10-07
|
| Locations: |
Montreal Heart Institute, Montreal, Quebec, H1T 1C8, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT01586442
|
